Graduate Institute of Clinical and Medical Science, School of Medicine, China Medical University, Taichung 40402, Taiwan.
Evid Based Complement Alternat Med. 2012;2012:371286. doi: 10.1155/2012/371286. Epub 2012 Jun 26.
Ganoderma tsugae (GT) is a traditional Chinese medicine that exhibits significant antitumor activities against many types of cancer. This study investigated the molecular mechanism by which GT suppresses the growth of doxorubicin-resistant lung adenocarcinoma H23/0.3 cells. Our results reveal that GT inhibits the viability of H23/0.3 cells in vitro and in vivo and sensitizes the growth suppression effect of doxorubicin on H23/0.3 cells. The data also show that GT induces S phase arrest by interfering with the protein expression of cyclin A, cyclin E, CDK2, and CDC25A. Furthermore, GT induces cellular apoptosis via induction of a mitochondria/caspase pathway. In addition, we also demonstrate that the suppression of cell proliferation by GT is through down-regulation of the PI3K/Akt signaling pathway. In conclusion, this study suggests that GT may be a useful adjuvant therapeutic agent in the treatment of lung cancer.
云芝(GT)是一种传统的中药,对多种癌症具有显著的抗肿瘤活性。本研究探讨了 GT 抑制多柔比星耐药肺腺癌细胞 H23/0.3 生长的分子机制。我们的结果表明,GT 在体外和体内均抑制 H23/0.3 细胞的活力,并增强多柔比星对 H23/0.3 细胞生长抑制作用。数据还表明,GT 通过干扰细胞周期蛋白 A、细胞周期蛋白 E、CDK2 和 CDC25A 的蛋白表达诱导 S 期停滞。此外,GT 通过诱导线粒体/胱天蛋白酶途径诱导细胞凋亡。此外,我们还证明 GT 通过下调 PI3K/Akt 信号通路抑制细胞增殖。总之,本研究表明 GT 可能是治疗肺癌的一种有用的辅助治疗药物。